Selective Bibliography of Dr. Joost Oppenheim
Cancer and Inflammation Program, NCI

""
Wednesday, November 17, 2021

1.  Chen CY, Ueha S, Ishiwata Y, Shichino S, Yokochi S, Yang D, Oppenheim JJ, Ogiwara H, Deshimaru S, Kanno Y, Aoki H, Ogawa T, Shibayama S, Matsushima K
Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8(+) T Cells
Cancer Immunology Research 9 (10):1214-1228 Oct 2021

2. Chen CY, Ueha S, Ishiwata Y, Yokochi S, Yang D, Oppenheim JJ, Ogiwara H, Shichino S, Deshimaru S, Shand FHW, Shibayama S, Matsushima K
Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice
Journal for ImmunoTherapy of Cancer 7 (1):21 Jan 29 2019

3. Nie Y, He J, Shirota H, Trivett AL, Yang D, Klinman DM, Oppenheim JJ, Chen X
Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer
Science Signaling 11 (511):Jan 2 2018

4.  Yang D, Han Z, Alam MM, Oppenheim JJ
High-mobility group nucleosome binding domain 1 (HMGN1) functions as a Th1-polarizing alarmin
Seminars in Immunology 38 49-53 Aug 2018
 

 

 

 



Date Last Updated: 11/1/2021